These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34365977)

  • 1. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa.
    Pitso L; Mofokeng TRP; Nel R
    BMC Endocr Disord; 2021 Aug; 21(1):159. PubMed ID: 34365977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
    Raal FJ; Blom DJ; Naidoo S; Bramlage P; Brudi P
    Cardiovasc J Afr; 2013 Sep; 24(8):330-8. PubMed ID: 24240385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor.
    Essop MR; Seedat F; Raal FJ
    S Afr Med J; 2023 Nov; 113(11):35-40. PubMed ID: 38525632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Dyslipidaemia Using an Algorithm of Lipid Profile Measures among Newly Diagnosed Type II Diabetes Mellitus Patients: A Cross-Sectional Study at Dormaa Presbyterian Hospital, Ghana.
    Anto EO; Obirikorang C; Annani-Akollor ME; Adua E; Donkor S; Acheampong E; Asamoah EA
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31330902
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of Dyslipidaemia among Type 2 Diabetes Mellitus Patients in the Western Cape, South Africa.
    Omodanisi EI; Tomose Y; Okeleye BI; Ntwampe SKO; Aboua YG
    Int J Environ Res Public Health; 2020 Nov; 17(23):. PubMed ID: 33255455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study.
    Selim S; Alam MS; Talukder SK; Kabir ML; Gaffar AJ; Kabir MA; Zarin N; Rahman S; Nabi MMU; Mustari M; Hossain MF; Raunak AIB; Hoque MA; Islam MR; Akter F; Hannan MA; Saifuddin M; Asaduzzaman M; Rahman MM; Ahammed A; Rafi MA; Hasan MJ; Kamrul-Hasan ABM
    BMC Endocr Disord; 2023 Dec; 23(1):268. PubMed ID: 38053073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).
    Klug E; Raal FJ; Marais AD; Smuts CM; Schamroth C; Jankelow D; Blom DJ; Webb DA
    S Afr Med J; 2018 Oct; 108(11b):973-1000. PubMed ID: 30421699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, patterns and determinants of dyslipidaemia among South African adults with comorbidities.
    Masilela C; Adeniyi OV; Benjeddou M
    Sci Rep; 2022 Jan; 12(1):337. PubMed ID: 35013433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, patterns and associated risk factors for dyslipidaemia among individuals attending the diabetes clinic at a tertiary hospital in Central Malawi.
    Filisa-Kaphamtengo F; Ngoma J; Mukhula V; Matemvu Z; Kapute D; Banda P; Phiri T; Mipando M; Hosseinipour MC; Katundu KGH
    BMC Cardiovasc Disord; 2023 Nov; 23(1):548. PubMed ID: 37946116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and control of dyslipidaemia among diabetic patients with microalbuminuria in a Chinese hospital.
    Wang SH; Wang L; Zhou Y; Guo YJ; Yuan Y; Li FF; Huang Y; Xia WQ
    Diab Vasc Dis Res; 2013 Mar; 10(2):169-78. PubMed ID: 22906862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.